Pioglitazone: Effect on CYP3A4 Activity

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Journal of clinical pharmacology

• Publication date

  2002-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1177/0091270002042012009PMID 12463723
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism.

  2002cited by this paper
• Interactions between Simvastatin and Troglitazone or Pioglitazone in Healthy Subjects

  2001cited by this paper
• No correlations between the urinary ratio of 6β-hydroxycortisol to free cortisol and pharmacokinetics of alprazolam

  2001cited by this paper
• Administration of troglitazone, but not pioglitazone, reduces insulin resistance caused by short-term dexamethasone (DXM) treatment by accelerating the metabolism of DXM.

  2001cited by this paper
• Circadian variation of the urinary 6β-hydroxycortisol to cortisol ratio that would reflect hepatic CYP3A activity

  2000cited by this paper
• Pioglitazone does not markedly alter oral contraceptive or hormone replacement therapy pharmacokinetics

  2000cited by this paper
• Drug interaction of St John's wort with cyclosporin.

  2000cited by this paper
• In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone.

  2000cited by this paper
• St John's Wort: effect on CYP3A4 activity.

  2000cited by this paper
• St John's Wort: Effect on CYP3A4 activity

  2000cited by this paper
• Effect of Troglitazone on the Pharmacokinetics of an Oral Contraceptive Agent

  1999cited by this paper
• Second thoughts about safety of St John's wort.

  1999cited by this paper
• Effect of Troglitazone on PK and PD of Atorvastatin

  1999cited by this paper
• Cytochrome P450 3A4 Activity in Premenopausal and Postmenopausal Women, Based on 6‐β‐Hydroxycortisol:Cortisol Ratios

  1998cited by this paper
• Effect of troglitazone on urinary excretion of 6beta-hydroxycortisol.

  1998cited by this paper
• Thiazolidinediones.

  1997cited by this paper
• A simple non-invasive procedure for the investigation of cytochrome P-450 IIIA dependent enzymes in humans.

  1991cited by this paper
• Quantitative determination by HPLC of urinary 6β-hydroxycortisol, an indicator of enzyme induction by rifampicin and antiepileptic drugs

  1979cited by this paper
• Prediction of Creatinine Clearance from Serum Creatinine

  1976cited by this paper
• Prediction of creatinine clearance from serum creatinine.

  1975cited by this paper

• Dietary Modulation of CYP3A4 and Its Impact on Statins and Antidiabetic Drugs: A Narrative Review

  2025cites this paper
• Current Pharmacological Intervention and Medical Management for Diabetic Kidney Transplant Recipients

  2021cites this paper
• The Adrenal Cortex and Its Disorders

  2021cites this paper
• Management of diabetes mellitus in patients undergoing liver transplantation

  2019cites this paper
• Quantitative evaluation of hepatic and intestinal induction of CYP3A in clinical practice

  2019influential citation
• Management Strategies for Posttransplant Diabetes Mellitus after Heart Transplantation: A Review

  2018cites this paper
• Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical Outcome

  2017cites this paper
• Drug-drug interactions between immunosuppressants and antidiabetic drugs in the treatment of post-transplant diabetes mellitus.

  2017cites this paper
• Studies on formulation development of gastroretentive drug delivery system for pioglitazone hydrochloride

  2014cites this paper
• A Current Review of Cytochrome P450 Interactions of Psychotropic Drugs

  2014cites this paper
• The Role of Pharmacogenetics in the Treatment of Diabetes Mellitus / ULOGA FARMAKOGENETIKE U LEČNJU DIJABETES MELITUSA

  2013cites this paper
• Alogliptin-Pioglitazone Combination Therapy: A Rational Approach to Treating Type 2 Diabetes Mellitus

  2012cites this paper
• Saxagliptin, a potent, selective inhibitor of DPP‐4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects

  2011cites this paper
• Effects of pioglitazone on subclinical atherosclerosis and insulin resistance in nondiabetic renal allograft recipients.

  2010cites this paper
• Pharmacogenetics of Anti-Diabetes Drugs

  2010cites this paper
• Hepatic Drug-Metabolizing Enzyme Induction and Implications for Preclinical and Clinical Risk Assessment

  2010cites this paper
• Is cytochrome modulation the new frontier for decreasing the risk of cataract?

  2009cites this paper
• Pharmacokinetic Interactions with Thiazolidinediones

  2007cites this paper
• Treating dyslipidaemia in the setting of diabetes mellitus and cardiovascular disease: a less commonly perceived therapeutic perspective in clinical practice

  2006cites this paper
• Augmentation of Myocardial Production of 15-Epi-Lipoxin-A4 by Pioglitazone and Atorvastatin in the Rat

  2006cites this paper
• Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions.

  2006cites this paper
• Effect of Genetic Polymorphisms in Cytochrome P450 (CYP) 2C9 and CYP2C8 on the Pharmacokinetics of Oral Antidiabetic Drugs

  2005cites this paper
• Rosiglitazone Therapy of Posttransplant Diabetes Mellitus

  2005cites this paper
• Pioglitazona. Revisión de sus efectos metabólicos y sistémicos

  2005cites this paper
• [Pioglitazone. Review of its metabolic and systemic effects].

  2005cites this paper
• Effect of pioglitazone on endotoxin-induced decreases in hepatic drug-metabolizing enzyme activity and expression of CYP3A2 and CYP2C11.

  2004cites this paper
• In vivo Bioequivalence of Oral Antidiabetic Agents: Pioglitazone Tablets

  2004influential citation
• No Clinically Relevant CYP3A Induction with the Dual Angiotensin‐Converting Enzyme/Neutral Endopeptidase Inhibitor, M100240

  2004cites this paper
• Pioglitazone in the Management of Diabetes Mellitus after Transplantation

  2004influential citation
• Thiazolidinediones as PPAR Agonists

  2004cites this paper
• Chapter 31. Enzyme induction — Mechanisms, assays, and relevance to drug discovery and development

  2003cites this paper
• Urinary 6β-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals

  2003cites this paper
• Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

  2003cites this paper